

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 09 August 2000 (09.08.00)	
<b>International application No.</b> PCT/US99/30337	<b>Applicant's or agent's file reference</b> BB1324 PCT
<b>International filing date</b> (day/month/year) 20 December 1999 (20.12.99)	<b>Priority date</b> (day/month/year) 21 December 1998 (21.12.98)
<b>Applicant</b> FAMODU, Omolayo, O. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
10 July 2000 (10.07.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b>  Pascal Piriou  Telephone No.: (41-22) 338.83.38
--	--

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

by fax and post

RECEIVED

MAR 22 2001

PCT

PATENT RECORDS  
CENTER

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

To:

SCHAEFFER, Andrew L.  
E.I. DU PONT DE NEMOURS AND COMPANY  
Legal Patent Records Center  
1007 Market Street  
Wilmington, DE 19898  
ETATS-UNIS D'AMERIQUE

FAX NO: (302) 773-0164

Date of mailing  
(day/month/year) 26.03.2001

Applicant's or agent's file reference  
BB1324 1

IMPORTANT NOTIFICATION

International application No.  
PCT/US99/30337

International filing date (day/month/year)  
20/12/1999

Priority date (day/month/year)  
21/12/1998

Applicant

E.I DU PONT DE NEMOURS AND COMPANY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

REY NOTED

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Büchler, S



Tel. +49 89 2399-8090



21 JE 2001

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference BB1324 1		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/30337	International filing date (day/month/year) 20/12/1999	Priority date (day/month/year) 21/12/1998	
International Patent Classification (IPC) or national classification and IPC C12N15/53			
Applicant E.I DU PONT DE NEMOURS AND COMPANY et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 807 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input checked="" type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand  10/07/2000		Date of completion of this report  26.03.2001	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer  Strobel, A  Telephone No. +49 89 2399 7362 	

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/30337

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

**Description, pages:**

1-24 as originally filed

**Claims, No.:**

1-24 as originally filed

**Sequence listing part of the description, pages:**

1-7, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/US99/30337**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**II. Priority**

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:  
**see separate sheet**

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	1-24
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-24
Industrial applicability (IA)	Yes:	Claims	1-24
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Re It m II**

**Pri rity**

Reference is made to the following document:

D1: SHOEMAKER, R., ET AL. : "public soybean EST project" EMBL SEQUENCE DATA LIBRARY, 15 December 1999 (1999-12-15), XP002139424 Heidelberg, Germany, Accession number AW234443

The present application claims priority of US Provisional Application No. 60/113,190. However, this priority document does not disclose isolated polynucleotides comprising a sequence that encodes a polypeptide of at least 494 amino acids showing at least 80% sequence identity with SEQ ID NOs:2 or 4.

Therefore, the priority for claims 1-10, 16, 17, and 19 is not valid. As a consequence, document D1 published after the priority date becomes relevant and belongs to the prior art as far as said claims are concerned.

**Re It m V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. This application concerns the cloning of an EST from soybean that might encode an isoflavone-2-hydroxylase, an enzyme involved in synthesis of plant isoflavonoids. Applicants sequence cDNA libraries obtained from various tissues of soybean. They perform BLAST similarity searches on the so obtained polynucleotide sequences (SEQ ID NOs.1 and 3) and identify them as 60 and 61% identical to isoflavone-2-hydroxylases of Glycyrrhiza echulenta and Cicer arietinum.

Applicants claim isolated polynucleotides encoding a polypeptide of at least 494 amino acids or at least 141 amino acids and showing at least 80% identity when compared to a polypeptide having SEQ ID NO: 1 or 2, chimeric genes comprising said polynucleotides, host cells and viruses comprising said polynucleotide, the polypeptide itself, compositions comprising the claimed polynucleotide or polypeptide of at least 494 or 141 amino acids, methods of selecting an isolated polynucleotide that affects the level of expression of a flavonoid biosynthetic enzyme, and finally methods of obtaining a nucleic acid fragment encoding a

flavonoid biosynthetic enzyme .

**2. Inventive step of claims 1-24**

The isolated polynucleotides/polypeptides claimed in said claims do not have any technical features. This is also evident from method claims 11 and 13 which relate to the selection of an isolated polynucleotide of claim 1 that affects the level of expression of a flavonoid biosynthetic enzyme. Said method claims therefore imply that not every isolated polynucleotide of claim 1 affects the expression level of a flavonoid biosynthetic enzyme in a plant cell, in other words that not every isolated polynucleotide of claim 1 has a technical effect. EST sequences to which a putative function is assigned by computational sequence comparisons cannot constitute inventive subject-matter. Applicants do not disclose that said polynucleotide/polypeptide sequences may affect the synthesis of a flavonoid biosynthetic enzyme or may probe/amplify such an enzyme, or finally may display the enzymatic activity of a flavonoid biosynthetic enzyme.

Especially in the light of D1, the underlying technical problem is to provide another EST sequence from soybean, which is a trivial problem.

Thus, claims 1-24 are obvious and do not fulfil the requirements of Article 33(3) PCT.

**Re It m VIII**

**Certain observations on the international application**

1. Method claims 11-15, and 20-22 refer to methods for the selection of an isolated polynucleotide that affects the expression of a flavonoid biosynthetic enzyme in a plant cell or a method of obtaining a nucleic acid fragment encoding a flavonoid biosynthetic enzyme. However, the entire application does not provide any experimental data showing that the claimed methods might affect the expression of a flavonoid biosynthetic enzyme or that said methods may lead to the isolation of a nucleic acid fragment encoding a flavonoid biosynthetic enzyme.  
Thus, said claims are not supported by the description (Article 6 PCT).
2. Method claims 11, 14, 15, 18, 21, and 22 relate to isolated polynucleotides comprising a nucleotide sequence of at least one of 30 contiguous nucleotides

**EXAMINATION REPORT - SEPARATE SHEET**

---

derived from an isolated polynucleotide of claim 1 or from polynucleotides with SEQ ID NO:1 or 3. This means that the polynucleotides of said method claims can be any polynucleotide, since they must comprise only one nucleotide present in a stretch of 30 nucleotides. Since the polynucleotide of the present method claims is not at all defined by technical features whatsoever, said claims are unclear (Article 6 PCT).





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/53, 15/82, 9/02, C12Q 1/68, 1/02</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/37652</b> <b>(43) International Publication Date:</b> 29 June 2000 (29.06.00)
<b>(21) International Application Number:</b> PCT/US99/30337 <b>(22) International Filing Date:</b> 20 December 1999 (20.12.99) <b>(30) Priority Data:</b> 60/113,190 21 December 1998 (21.12.98) US <b>(71) Applicant (for all designated States except US):</b> E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FAMODU, Omolayo, O. [US/US]; 216 Barrett Run Place, Newark, DE 19702 (US). MCGONIGLE, Brian [US/US]; 1707 North Union Street, Wilmington, DE 19806 (US). ODELL, Joan, T. [US/US]; P.O. Box 826, Unionville, PA 19375 (US). FADER, Gary, M. [US/US]; 1000 Woods Lane, Landenberg, PA 19350 (US). FALCO, Saverio, Carl [US/US]; 1902 Miller Road, Arden, DE 19810 (US). <b>(74) Agent:</b> FEULNER, Gregory, J.; E.I. du Pont de Nemours and Company, Legal Patent Record Center, 1007 Market Street, Wilmington, DE 19898 (US).		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> FLAVONOID BIOSYNTHETIC ENZYMES  <b>(57) Abstract</b> <p>This invention relates to an isolated nucleic acid fragment encoding a flavonoid biosynthetic enzyme. The invention also relates to the construction of a chimeric gene encoding all or a portion of the flavonoid biosynthetic enzyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the flavonoid biosynthetic enzyme in a transformed host cell.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SEQUENCE LISTING

&lt;110&gt; E. I. du Pont de Nemours and Company

&lt;120&gt; Flavonoid Biosynthetic Enzymes

&lt;130&gt; BB1324

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/113,190

&lt;151&gt; 1998-12-21

&lt;160&gt; 6

&lt;170&gt; Microsoft Office 97

&lt;210&gt; 1

&lt;211&gt; 1859

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;400&gt; 1

```

gaaaacactg acagacagca tagtctctgg tgcaagaatc aattgagcaa gcatgggaat 60
gttggttggt gtggtctcat acgctgtcct ttctctgggt ctattcctcg gcgtgaagtt 120
tgttttccaa agcagaaaat tgagaaacat accaccaggt cctcctcctc ttcccataat 180
aggaaacctt aacctcctcg aacagccaat ccaccgtttc ttccaacgca tgtcgaaaca 240
gtacggcaac gtggtttccc tctggttcgg ttacagtcgt gccgttgta tctcctctcc 300
aacagcatac caagaatgct tcaccaaaca cgacgttgcc ttggccaacc ggctaccttc 360
tctctcggga aaatacatct tctacaacaa caccaccgta ggctcctgct cccacggcga 420
gcaactggcg aacctccgcc gcatcacgcg cctggacgtc ctctccacgc agcgcgtcca 480
ctccttctcc ggaatccgga gcgacgagac gaagcgtctg atgcagaggt tgggtgctggc 540
caagaactcg aacgaggaag agtttgcgcg agtggagatt agttcgatgt tcaacgactt 600
aacttacaac aacataatga ggatgatatc ggggaagagg ttttacggag aggagagtga 660
gatgaagaac gttgaggaag cgagggagtt cagagagact gtgacagaaa tgttggaact 720
catgggcttg gctaacaagg gagatcactt gcctttcctc aggtgggttcg attttcagaa 780
tgtggagaag cgcttaaaga gtatcagtaa gaggtacgat tccatcttga ataagatcct 840
tcatgagaac cgtgccagca atgaccgcca gaattccatg atcgatcatc tcctcaaact 900
gcaagagacc cagcctcagt actacactga ccaaatcatc aaaggccttg ctctggccat 960
gcttttttgt ggaactgact catcaactgg gacttttagag tggtcattat ctaatttatt 1020
gaatcaccca gaggtgttga agaaggcaag agatgaattg gacactcaag tgggacaaga 1080
ccgcttggtt aatgagtcag accttccaaa acttccatat cttaggaaga tcatccttga 1140
gacacttagg ttgtaccccc cggccccaat tctaatacct catgtgtctt cagaagatat 1200
tacaattgaa ggattcaata tcccacgaga cacaattgtg atcattaatg gttggggcat 1260
gcagagagat cctcagttgt ggaatgatgc cacatgcttt aaacctgaga ggtttgatgt 1320
ggaaggagag gagaaaaagt tggtagcatt tggcatggga agaagggtt gccacaggaga 1380
acccatggct atgcaaagtg tcagctttac tttgggattg ttgattcaat gttttgactg 1440
gaaacgagta agtgaggaaa agcttgatat gacagagaac aattggatca ccttgtcaag 1500
gttaattcca ttggaggcca tgtgcaaggc tcgcccactt gccactaaaa ttggaattta 1560
attattaata gtatttttat ttggtaaact tgggtgattc agaattctaat acttataatt 1620
ttagtggtga agagtgggtg tcatatatac atttcaaaat taataatctt tgtccaaaaa 1680
tcatccatgg acaactatat gtcaattgac atctagagag aaatatagat ataagaatat 1740
ttatatttta ttactcttct ttatcttatg tgtcaaggcc cattgtagaa ttgggtgagc 1800
attaacatat atcaatatgg tataccgccc agttttctca aataaatttc tttactttc 1859

```

&lt;210&gt; 2

&lt;211&gt; 499

&lt;212&gt; PRT

&lt;213&gt; Glycine max

```

<400> 2
Leu Leu Val Val Val Ser Tyr Ala Val Leu Phe Leu Val Leu Phe Leu
 1          5          10          15
Gly Val Lys Phe Val Phe Gln Ser Arg Lys Leu Arg Asn Ile Pro Pro
          20          25          30
Gly Pro Pro Pro Leu Pro Ile Ile Gly Asn Leu Asn Leu Leu Glu Gln
          35          40          45
Pro Ile His Arg Phe Phe Gln Arg Met Ser Lys Gln Tyr Gly Asn Val
          50          55          60
Val Ser Leu Trp Phe Gly Ser Arg Leu Ala Val Val Ile Ser Ser Pro
          65          70          75          80
Thr Ala Tyr Gln Glu Cys Phe Thr Lys His Asp Val Ala Leu Ala Asn
          85          90          95
Arg Leu Pro Ser Leu Ser Gly Lys Tyr Ile Phe Tyr Asn Asn Thr Thr
          100          105          110
Val Gly Ser Cys Ser His Gly Glu His Trp Arg Asn Leu Arg Arg Ile
          115          120          125
Thr Ala Leu Asp Val Leu Ser Thr Gln Arg Val His Ser Phe Ser Gly
          130          135          140
Ile Arg Ser Asp Glu Thr Lys Arg Leu Met Gln Arg Leu Val Leu Ala
          145          150          155          160
Lys Asn Ser Asn Glu Glu Glu Phe Ala Arg Val Glu Ile Ser Ser Met
          165          170          175
Phe Asn Asp Leu Thr Tyr Asn Asn Ile Met Arg Met Ile Ser Gly Lys
          180          185          190
Arg Phe Tyr Gly Glu Glu Ser Glu Met Lys Asn Val Glu Glu Ala Arg
          195          200          205
Glu Phe Arg Glu Thr Val Thr Glu Met Leu Glu Leu Met Gly Leu Ala
          210          215          220
Asn Lys Gly Asp His Leu Pro Phe Leu Arg Trp Phe Asp Phe Gln Asn
          225          230          235          240
Val Glu Lys Arg Leu Lys Ser Ile Ser Lys Arg Tyr Asp Ser Ile Leu
          245          250          255
Asn Lys Ile Leu His Glu Asn Arg Ala Ser Asn Asp Arg Gln Asn Ser
          260          265          270
Met Ile Asp His Leu Leu Lys Leu Gln Glu Thr Gln Pro Gln Tyr Tyr
          275          280          285
Thr Asp Gln Ile Ile Lys Gly Leu Ala Leu Ala Met Leu Phe Gly Gly
          290          295          300

```

Thr Asp Ser Ser Thr Gly Thr Leu Glu Trp Ser Leu Ser Asn Leu Leu  
 305 310 315 320  
 Asn His Pro Glu Val Leu Lys Lys Ala Arg Asp Glu Leu Asp Thr Gln  
 325 330 335  
 Val Gly Gln Asp Arg Leu Leu Asn Glu Ser Asp Leu Pro Lys Leu Pro  
 340 345 350  
 Tyr Leu Arg Lys Ile Ile Leu Glu Thr Leu Arg Leu Tyr Pro Pro Ala  
 355 360 365  
 Pro Ile Leu Ile Pro His Val Ser Ser Glu Asp Ile Thr Ile Glu Gly  
 370 375 380  
 Phe Asn Ile Pro Arg Asp Thr Ile Val Ile Ile Asn Gly Trp Gly Met  
 385 390 395 400  
 Gln Arg Asp Pro Gln Leu Trp Asn Asp Ala Thr Cys Phe Lys Pro Glu  
 405 410 415  
 Arg Phe Asp Val Glu Gly Glu Glu Lys Lys Leu Val Ala Phe Gly Met  
 420 425 430  
 Gly Arg Arg Ala Cys Pro Gly Glu Pro Met Ala Met Gln Ser Val Ser  
 435 440 445  
 Phe Thr Leu Gly Leu Leu Ile Gln Cys Phe Asp Trp Lys Arg Val Ser  
 450 455 460  
 Glu Glu Lys Leu Asp Met Thr Glu Asn Asn Trp Ile Thr Leu Ser Arg  
 465 470 475 480  
 Leu Ile Pro Leu Glu Ala Met Cys Lys Ala Arg Pro Leu Ala Thr Lys  
 485 490 495  
 Ile Gly Ile

<210> 3  
 <211> 1698  
 <212> DNA  
 <213> Glycine max

<400> 3  
 cagtaataac aatgtctcct ttcttatctt actctcttct ttccctcgtg ttcttcttca 60  
 ctctcaagta ctttttccaa agaagcagaa aagtacgaaa cctgccacct ggctccgactc 120  
 ctcttcctat aatcggaac cttaacctcg ttgaacaacc tatacacctg ttcttccacc 180  
 gcatgtccca aaaatatgga aacatcatat cccttttggt tgggtcacgt cttgttggtg 240  
 ttgtttcatc acccacagcg taccaagaat gtttcaccaa acatgatgtt accttggcca 300  
 acagggtaac ctccctctcg ggaaaataca tattctacga caacaccacc gtagggctct 360  
 gctcccacgg cgagcactgg cgcaacctcc gccgcataac ctctctcgac gttctatoga 420  
 cgcagcgcgt ccaactcctc tccggaatcc ggagcgacga gacgaagagg ttgatacaca 480  
 ggctggccag ggactccggg aaagattttg cgcgcgtgga gatgacctcc aagtttgctg 540  
 acttgacgta caacaacatc atgaggatga ttccggggaa gcggttttac ggagaagaga 600  
 gtgaacttaa caacgttgag gaagcgaagg agttcagaga cactgtgaat gagatgctgc 660  
 aactcatggg gttggctaac aaggagatc acttaccttt cctaaggtgg ttcgattttc 720  
 agaacgtgga gaagaggttg aagaatatca gtaagaggta tgataccatc ttgaataaga 780  
 tccttgatga gaaccgtaac aacaaggacc gcgagaattc catgattggt catctcctca 840  
 aactgcaaga gacacagcct gactattata ccgaccaaact catcaaaggc cttgctttgg 900

```

ctatgctctt  tgggtggaaca  gactcgtcaa  ctggaacttt  agagtgggca  ttatctaatt  960
tagtgaatga  cccagagggtg  ctgcagaagg  caagagatga  gttggacgct  caagtaggac  1020
cagatcggct  gttaaagtga  tcagaccttc  caaaacttcc  ttatctcagg  aagatagttc  1080
ttgaaacact  taggttgtag  cctccggctc  caattctaata  accacacgtg  gcttcagaag  1140
acatcaatat  cgaaggattc  aatgttccac  gagacacaat  tgtgattatt  aatgggtggg  1200
ccatgcaaag  agatcctaag  atatggaaaag  atgcgacaag  ctttaaacct  gagagggttg  1260
atgaagaagg  agaggagaag  aaattggtag  catttggtat  gggaagaagg  gcttgcccag  1320
gagaacccat  ggctatgcaa  agtggttagct  atactttggg  attaagtatt  caatgttttg  1380
actggaaacg  agtaagtga  aagaagcttg  atatgacaga  gaataattgg  atcaccttgt  1440
caaggttaat  tccattggag  gctatgtgta  aagcccgcc  actcgccagc  aaagttgaaa  1500
gttattaaca  atattttatt  tgggtatatt  gggtgaggat  ctaataactca  taatttcggg  1560
gtgtaagtct  atgcatgtta  aaattaataa  tatttgcgt  atgtccacaa  ggccaaatgt  1620
agtactgggt  gtggatttgc  atatacaata  tcaatattgt  ataaatccca  gtttccttga  1680
ataaatttct  ttactttc

```

<210> 4  
 <211> 494  
 <212> PRT  
 <213> Glycine max

<400> 4  
 Leu Ser Tyr Ser Leu Leu Ser Leu Val Phe Phe Phe Thr Leu Lys Tyr  
 1 5 10 15  
 Leu Phe Gln Arg Ser Arg Lys Val Arg Asn Leu Pro Pro Gly Pro Thr  
 20 25 30  
 Pro Leu Pro Ile Ile Gly Asn Leu Asn Leu Val Glu Gln Pro Ile His  
 35 40 45  
 Arg Phe Phe His Arg Met Ser Gln Lys Tyr Gly Asn Ile Ile Ser Leu  
 50 55 60  
 Trp Phe Gly Ser Arg Leu Val Val Val Val Ser Ser Pro Thr Ala Tyr  
 65 70 75 80  
 Gln Glu Cys Phe Thr Lys His Asp Val Thr Leu Ala Asn Arg Val Arg  
 85 90 95  
 Ser Leu Ser Gly Lys Tyr Ile Phe Tyr Asp Asn Thr Thr Val Gly Ser  
 100 105 110  
 Cys Ser His Gly Glu His Trp Arg Asn Leu Arg Arg Ile Thr Ser Leu  
 115 120 125  
 Asp Val Leu Ser Thr Gln Arg Val His Ser Phe Ser Gly Ile Arg Ser  
 130 135 140  
 Asp Glu Thr Lys Arg Leu Ile His Arg Leu Ala Arg Asp Ser Gly Lys  
 145 150 155 160  
 Asp Phe Ala Arg Val Glu Met Thr Ser Lys Phe Ala Asp Leu Thr Tyr  
 165 170 175  
 Asn Asn Ile Met Arg Met Ile Ser Gly Lys Arg Phe Tyr Gly Glu Glu  
 180 185 190  
 Ser Glu Leu Asn Asn Val Glu Glu Ala Lys Glu Phe Arg Asp Thr Val  
 195 200 205

Asn Glu Met Leu Gln Leu Met Gly Leu Ala Asn Lys Gly Asp His Leu  
 210 215 220  
 Pro Phe Leu Arg Trp Phe Asp Phe Gln Asn Val Glu Lys Arg Leu Lys  
 225 230 235 240  
 Asn Ile Ser Lys Arg Tyr Asp Thr Ile Leu Asn Lys Ile Leu Asp Glu  
 245 250 255  
 Asn Arg Asn Asn Lys Asp Arg Glu Asn Ser Met Ile Gly His Leu Leu  
 260 265 270  
 Lys Leu Gln Glu Thr Gln Pro Asp Tyr Tyr Thr Asp Gln Ile Ile Lys  
 275 280 285  
 Gly Leu Ala Leu Ala Met Leu Phe Gly Gly Thr Asp Ser Ser Thr Gly  
 290 295 300  
 Thr Leu Glu Trp Ala Leu Ser Asn Leu Val Asn Asp Pro Glu Val Leu  
 305 310 315 320  
 Gln Lys Ala Arg Asp Glu Leu Asp Ala Gln Val Gly Pro Asp Arg Leu  
 325 330 335  
 Leu Asn Glu Ser Asp Leu Pro Lys Leu Pro Tyr Leu Arg Lys Ile Val  
 340 345 350  
 Leu Glu Thr Leu Arg Leu Tyr Pro Pro Ala Pro Ile Leu Ile Pro His  
 355 360 365  
 Val Ala Ser Glu Asp Ile Asn Ile Glu Gly Phe Asn Val Pro Arg Asp  
 370 375 380  
 Thr Ile Val Ile Ile Asn Gly Trp Ala Met Gln Arg Asp Pro Lys Ile  
 385 390 395 400  
 Trp Lys Asp Ala Thr Ser Phe Lys Pro Glu Arg Phe Asp Glu Glu Gly  
 405 410 415  
 Glu Glu Lys Lys Leu Val Ala Phe Gly Met Gly Arg Arg Ala Cys Pro  
 420 425 430  
 Gly Glu Pro Met Ala Met Gln Ser Val Ser Tyr Thr Leu Gly Leu Met  
 435 440 445  
 Ile Gln Cys Phe Asp Trp Lys Arg Val Ser Glu Lys Lys Leu Asp Met  
 450 455 460  
 Thr Glu Asn Asn Trp Ile Thr Leu Ser Arg Leu Ile Pro Leu Glu Ala  
 465 470 475 480  
 Met Cys Lys Ala Arg Pro Leu Ala Ser Lys Val Glu Ser Tyr  
 485 490

<210> 5  
 <211> 843  
 <212> DNA  
 <213> Glycine max

<220>  
 <221> unsure  
 <222> (476)

<220>  
 <221> unsure  
 <222> (657)

<220>  
 <221> unsure  
 <222> (703)

<220>  
 <221> unsure  
 <222> (712)

<220>  
 <221> unsure  
 <222> (789)

<220>  
 <221> unsure  
 <222> (843)

<400> 5  
 ttcaactctca agcttcaagc atgactcctt tttacttcct cctatttgcc ttcacccctt 60  
 tcctctccat aaacttcttg atccaaacaa gaaggttcaa aaaccttcct ccgggaccat 120  
 tttctttccc tataatcgga aacctccacc aactcaagca acccctccac cgcacgttcc 180  
 atgccttata acaaaaaatat ggccctattt tctccctctg gttcggctcc cgttttgctg 240  
 tcgtcgtttc gtcgcccgtc gcggtgcaag aatgcttcac caagaacgac atcgtccttg 300  
 ccaaccgccc tcacttcctc accggcaagt atatagggtta caacaacacc accgtcgccg 360  
 tttcccccta cggcgaccac tggcgcaacc tccgcccgcac catggcgctc gaggttctct 420  
 ccaccaccg gataaaactc ttcttggaat atcgaggggg acgaagatca tgaggntcgt 480  
 gcaaaagctt gctcgggact cgcgcaatgg gttcaccaaa gtagaactta aatccagggt 540  
 ttcggagatg acatttaaca ctataatgag gatggtgtca gggaagaggt actatggtga 600  
 agactgtgat gtgagtgatg tacaggaagc aagcaattta gagagatcat taaagantgg 660  
 tgacgttagg aggggctaata aacctgggga ctcttggttt gcntggtggt tntttgatgg 720  
 ttggaaagag cttaaagagga tagtagagaa cgatcggtta caggaccatt gtagcatcta 780  
 tggaacacnt gcatacatga taatatctct gccacacaac acaccgatat aacgttaatc 840  
 atn 843

<210> 6  
 <211> 141  
 <212> PRT  
 <213> Glycine max

<400> 6  
 Phe Leu Leu Phe Ala Phe Ile Leu Phe Leu Ser Ile Asn Phe Leu Ile  
 1 5 10 15  
 Gln Thr Arg Arg Phe Lys Asn Leu Pro Pro Gly Pro Phe Ser Phe Pro  
 20 25 30  
 Ile Ile Gly Asn Leu His Gln Leu Lys Gln Pro Leu His Arg Thr Phe  
 35 40 45  
 His Ala Leu Ser Gln Lys Tyr Gly Pro Ile Phe Ser Leu Trp Phe Gly  
 50 55 60



Ser	Arg	Phe	Val	Val	Val	Val	Ser	Ser	Pro	Leu	Ala	Val	Gln	Glu	Cys
65						70				75					80
Phe	Thr	Lys	Asn	Asp	Ile	Val	Leu	Ala	Asn	Arg	Pro	His	Phe	Leu	Thr
				85					90					95	
Gly	Lys	Tyr	Ile	Gly	Tyr	Asn	Asn	Thr	Thr	Val	Ala	Val	Ser	Pro	Tyr
			100					105					110		
Gly	Asp	His	Trp	Arg	Asn	Leu	Arg	Arg	Ile	Met	Ala	Leu	Glu	Val	Leu
		115					120					125			
Ser	Thr	His	Arg	Ile	Asn	Ser	Phe	Leu	Glu	Asn	Arg	Arg			
	130					135					140				



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/53, 15/82, 9/02, C12Q 1/68, 1/02</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/37652</b>  <b>(43) International Publication Date:</b> 29 June 2000 (29.06.00)
<b>(21) International Application Number:</b> PCT/US99/30337 <b>(22) International Filing Date:</b> 20 December 1999 (20.12.99)  <b>(30) Priority Data:</b> 60/113,190                      21 December 1998 (21.12.98)      US  <b>(71) Applicant (for all designated States except US):</b> E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FAMODU, Omolayo, O. [US/US]; 216 Barrett Run Place, Newark, DE 19702 (US). MCGONIGLE, Brian [US/US]; 1707 North Union Street, Wilmington, DE 19806 (US). ODELL, Joan, T. [US/US]; P.O. Box 826, Unionville, PA 19375 (US). FADER, Gary, M. [US/US]; 1000 Woods Lane, Landenberg, PA 19350 (US). FALCO, Saverio, Carl [US/US]; 1902 Miller Road, Arden, DE 19810 (US).  <b>(74) Agent:</b> FEULNER, Gregory, J.; E.I. du Pont de Nemours and Company, Legal Patent Record Center, 1007 Market Street, Wilmington, DE 19898 (US).		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 16 November 2000 (16.11.00)
<b>(54) Title:</b> FLAVONOID BIOSYNTHETIC ENZYMES  <b>(57) Abstract</b>  <p>This invention relates to an isolated nucleic acid fragment encoding a flavonoid biosynthetic enzyme. The invention also relates to the construction of a chimeric gene encoding all or a portion of the flavonoid biosynthetic enzyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the flavonoid biosynthetic enzyme in a transformed host cell.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1324 PCT1</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 30337</b>	International filing date (day/month/year) <b>20/12/1999</b>	(Earliest) Priority Date (day/month/year) <b>21/12/1998</b>
Applicant <b>E.I DU PONT DE NEMOURS AND COMPANY et al</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

P 99/30337

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/82 C12N9/02 C12Q1/68 C12Q1/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, STRAND, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A ✓	AKASHI TOMOYOSHI ET AL: "CYHP81E1, a cytochrome P450 cDNA of licorice (Glycyrrhiza echinata L.), encodes isoflavone 2'-hydroxylase." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS OCT. 9, 1998, vol. 251, no. 1, 9 October 1998 (1998-10-09), pages 67-70, XP000914524 ISSN: 0006-291X cited in the application the whole document --- -/--	

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 July 2000

Date of mailing of the international search report

17/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30337

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AKASHI, T., ET AL. : "cloning of cytochrome P450 cDNAs from cultured Glycyrrhiza echinata L. cells and their transcriptional activation by elicitor-treatment" EMBL SEQUENCE DATA LIBRARY, 23 September 1997 (1997-09-23), XP002139419 heidelberg, germany accession no. AB001379 ---	
A	DANIEL, S., ET AL. : "elicitor-induced metabolic changes in cell cultures of chickpea (Cicer arietinum L.) cultivars resistant and susceptible to Ascochyta blight. I. investigations of enzyme activities involved in isoflavone and pterocarpan phytoalexin biosynthesis" PLANTA, vol. 182, no. 2, 1990, pages 270-278, XP000914222 the whole document ---	
A	OVERKAMP, S. AND BARZ, W.: "cloning of two Cicer arietinum L. cDNAs encoding cytochrome P450 highly homologous to isoflavone 2' hydroxylase from licorice" EMBL SEQUENCE DATA LIBRARY, 6 November 1998 (1998-11-06), XP002139420 heidelberg, germany accession no. AJ012581 ---	
A	HINDERER W ET AL: "MICROSOMAL ISOFLAVONE 2' AND 3'-HYDROXYLASES FROM CHICKPEA CICER-ARIETINUM L. CELL SUSPENSIONS INDUCED FOR PTEROCARPAN PHYTOALEXIN FORMATION" FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS 1987, vol. 214, no. 1, 1987, pages 101-106, XP002139422 ISSN: 0014-5793 the whole document ---	
A	KESSMANN H ET AL: "STRESS RESPONSES IN ALFALFA MEDICAGO-SATIVA L. V. CONSTITUTIVE AND ELICITOR-INDUCED ACCUMULATION OF ISOFLAVONOID CONJUGATES IN CELL SUSPENSION CULTURES" PLANT PHYSIOLOGY (BETHESDA) 1990, vol. 94, no. 1, 1990, pages 227-232, XP002139423 ISSN: 0032-0889 the whole document ---	
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30337

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CLEMENS STEPHAN ET AL: "Characterization of cytochrome P450-dependent isoflavone hydroxylases from chickpea."            PHYTOCHEMISTRY (OXFORD) 1993,            vol. 32, no. 3, 1993, pages 653-657,            XP000920560            ISSN: 0031-9422</p>	
P,X	<p>SHOEMAKER, R., ET AL. : "public soybean EST project"            EMBL SEQUENCE DATA LIBRARY,            15 December 1999 (1999-12-15),            XP002139424            heidelberg, germany            accession no. AW234443</p>	1-4

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30337

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/82 C12N9/02 C12Q1/68 C12Q1/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, STRAND, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AKASHI TOMOYOSHI ET AL: "CYHP81E1, a cytochrome P450 cDNA of licorice (Glycyrrhiza echinata L.), encodes isoflavone 2'-hydroxylase." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS OCT. 9, 1998, vol. 251, no. 1, 9 October 1998 (1998-10-09), pages 67-70, XP000914524 ISSN: 0006-291X cited in the application the whole document --- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

4 July 2000

Date of mailing of the international search report

17/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S



## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>AKASHI, T., ET AL. : "cloning of cytochrome P450 cDNAs from cultured Glycyrrhiza echinata L. cells and their transcriptional activation by elicitor-treatment" EMBL SEQUENCE DATA LIBRARY, 23 September 1997 (1997-09-23), XP002139419 heidelberg, germany accession no. AB001379</p>	
A	<p>DANIEL, S., ET AL. : "elicitor-induced metabolic changes in cel cultures of chickpea (Cicer arietinum L.) cultivars resistant and susceptible to Ascochyta rabiei. I. investigations of enzyme activities involved in isoflavone and pterocarpin phytoalexin biosynthesis" PLANTA, vol. 182, no. 2, 1990, pages 270-278, XP000914222 the whole document</p>	
A	<p>OVERKAMP, S. AND BARZ, W.: "cloning of two Cicer arietinum L. cDNAs encoding cytochrome P450 highly homologous to isoflavone 2' hydroxylase from licorice" EMBL SEQUENCE DATA LIBRARY, 6 November 1998 (1998-11-06), XP002139420 heidelberg, germany accession no. AJ012581</p>	
A	<p>HINDERER W ET AL: "MICROSOMAL ISOFLAVONE 2' AND 3'-HYDROXYLASES FROM CHICKPEA CICER-ARIETINUM L. CELL SUSPENSIONS INDUCED FOR PTEROCARPAN PHYTOALEXIN FORMATION" FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS 1987, vol. 214, no. 1, 1987, pages 101-106, XP002139422 ISSN: 0014-5793 the whole document</p>	
A	<p>KESSMANN H ET AL: "STRESS RESPONSES IN ALFALFA MEDICAGO-SATIVA L. V. CONSTITUTIVE AND ELICITOR-INDUCED ACCUMULATION OF ISOFLAVONOID CONJUGATES IN CELL SUSPENSION CULTURES" PLANT PHYSIOLOGY (BETHESDA) 1990, vol. 94, no. 1, 1990, pages 227-232, XP002139423 ISSN: 0032-0889 the whole document</p>	

-/--

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CLEMENS STEPHAN ET AL: "Characterization of cytochrome P450-dependent isoflavone hydroxylases from chickpea." PHYTOCHEMISTRY (OXFORD) 1993, vol. 32, no. 3, 1993, pages 653-657, XP000920560 ISSN: 0031-9422	
P,X	SHOEMAKER, R., ET AL. : "public soybean EST project" EMBL SEQUENCE DATA LIBRARY, 15 December 1999 (1999-12-15), XP002139424 heidelberg, germany accession no. AW234443	1-4

cc: U.S. file ✓

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

RECEIVED

(PCT Rule 44.1) JUL 24 2000

PATENT RECORDS  
CENTER

To:

E.I. DU PONT DE NEMOURS AND COMPANY  
Legal/Patent Records Center  
Attn. FEULNER, Gregory J. WRM  
1007 Market Street  
Wilmington, Delaware 19898  
UNITED STATES OF AMERICADate of mailing  
(day/month/year)

17/07/2000

Applicant's or agent's file reference

BB1324 PCT# MMc

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 99/ 30337

International filing date  
(day/month/year)

20/12/1999

Applicant

E.I DU PONT DE NEMOURS AND COMPANY et al

- 1.
- ☒
- The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35**For more detailed instructions,** see the notes on the accompanying sheet.

- 2.
- ☐
- The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

- 3.
- ☐
- With regard to the protest**
- against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

- 4.
- Further action(s):**
- The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mireille Claudepierre

TRB NOTED

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

## INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

### What documents must/may accompany the amendments?

#### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

**"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

**Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

**Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.